期刊文献+

马兜铃酸Ⅰ对大鼠体内PI3K/Akt/NF-кB通路的影响к 被引量:16

Effect of Aristolochic AcidⅠ on PI3K/Akt/NFкB Signaling Pathway in Rats
下载PDF
导出
摘要 目的探讨马兜铃酸Ⅰ(Aristolochic acidⅠ,AAⅠ)诱导的马兜铃酸肾病可能病变机制,分析其对PI3K/Akt/NFкB通路的影响。方法 SD雄性大鼠按随机数字表法分为空白对照组以及AAⅠ高、低剂量(9.0、2.25mg/kg)组,连续腹腔注射给药14d后,取血清检测肌酐(Cr)、尿素氮(BUN)、碱性磷酸酶(AKP),并用HE法染色观察肾脏病理组织学变化;用蛋白免疫印迹(Western blot)法分析PI3K、Akt、NFкB蛋白的表达,此外用免疫组织化学方法分析AAⅠ对肾脏组织IL-6和TNF-的表达变化。结果给药AAⅠ组与对照组比较,Cr、BUN、AKP水平显著升高(P<0.05);肾脏病理学检查显示肾脏病变和炎症改变,IL-6、TNF-表达显著增多(P<0.01);PI3K、Akt、NFкB及其磷酸化蛋白表达水平增高。结论 AAⅠ能导致肾脏毒性,并且可能通过激活PI3K/Akt/NFкB通路,诱发炎症,从而加重肾脏组织病理学改变。 ABSTRACT:OBJECTIVE To investigate the potential mechanism of aristolochic acid Ⅰ(AAⅠ)on aristolochic acid nephrop-athy and the effect of AAⅠ on PI3K/Akt/NF-κB signaling pathway in rats.METHODS 27 male SD rats were randomly di-vided into three groups:control group,AAⅠ low-dose group(2.25 mg/kg) and AAⅠ high-dose group (9.0 mg/kg).Rats were intraperitoneally injected with AAⅠ once daily for 14 d.Then the serum were taken to determine the content of Cr,BUN and AKP in rats;renal pathological changes were examined by HE staining;the expression levels of PI3K,Akt,NF-κB were analyzed by Western blot;the expression changes of IL-6 and TNF-αwere detected by immunohistochemical assay.RESULTS Compared with control group,the levels of Cr,BUN and AKP in AAⅠ groups were increased significantly(P 〈0.05);kidney pathological examination revealed the improvement of kidney disease and inflammation;the expressions of IL-6 and TNF-αwere increased significantly(P 〈0.01);the expression of PI3K,Akt and NF-κB were up-regulated.CONCLUSION AAⅠ can induce the kidney injury and inflammation and activate the PI3K/Akt/NF-κB signaling pathway,thus worsen patho-logical changes of kidney tissue.
出处 《南京中医药大学学报》 CAS CSCD 北大核心 2015年第3期250-253,共4页 Journal of Nanjing University of Traditional Chinese Medicine
基金 江苏省自然科学基金(BK2012852) 江苏省高校优势学科建设工程资助项目(2011XYZ4-003) 江苏省普通高校研究生科研创新计划(CXLX13_594)
关键词 马兜铃酸Ⅰ 肾损伤 PI3K/Akt/NFкB通路 炎症 kidney injury PI3K/Akt/NF-κB signaling pathway inflammation
  • 相关文献

参考文献16

  • 1Martinek V, Kubickova B, Arlt VM, et al. Comparison of acti i vation of Aristolochic acid I and H with NADPH : quinone oxi doreductase, sulphotransferases and N-aeetyltranferases[J]:Neu ro Endocrinol Lett,2011,32 Suppl 1:57-70.
  • 2Shibutani S, Dong H, Suzuki N, et al. Selective toxicity ,of aris tolochic acids I and II[J]. Drug Metab Dispos,2007,85(7) 1217-1222.
  • 3唐功耀,田雪飞,谌贻璞.马兜铃酸对人肾细胞作用的实验研究[J].中华肾脏病杂志,2002,18(4):266-269. 被引量:49
  • 4Chen YY,Chung JG,Wu HC, et al. Aristolochic acid suppresses DNA repair and triggers oxidative DNA damage in human kid- ney proximal tubular cells[J]. Oncol Rep,2010,24(1) :141-153.
  • 5Zhou L,Fu P, H uang XR, et al. Mechanism of chronic aristolo- chic acid nephropathy= role of Smad3[J]. Am J Physiol Renal Physiol,2010,298(4) =F1006-F1017.
  • 6Nedelko T, Arlt VM, Phillips DH, et al. TP53 mutation signa ture supports involvement of Aristolochic acid in the aetiology of endemic nephropathy- associated tumours[J]. Int J Cancer, 2009,124(4) =987 -990.
  • 7Jelakovie B, Karanovic S, Vukovic-Lela I, et al. Aristolactam- DNA adducts are a biomarker of environmental exposure to aris- tolochic acid[J]. Kidney Int, 2012,81 (6) = 559-567.
  • 8Pozdzik AA, Salmon IJ, Husson CP, et al. Patterns of intersti- tial inflammation during the evolution of renal injury in experi mental aristolochic acid nephropathy[J]. Nephrol Dial Trans plant, 2008,23(8) : 2480-2491.
  • 9Pozdzik AA, Berton A, Schmeiser HH, et al. Aristolochic acid nephropathy revisited: a place for innate and adaptive immuni ty? [J].Histopathology. 2010,56(4) :449-463.
  • 10Viatour P, Merville MP, Bours V, et al. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and int'lammation[J]. Trends Biochem Sci, 2005,30 ( 1 ) = 43-52.

二级参考文献31

  • 1赵云,阮金兰,蔡亚玲.石南藤中马兜铃内酰胺类化学成分研究[J].中药材,2005,28(3):191-193. 被引量:9
  • 2谭昭,田雪飞,谌贻璞,董鸿瑞.肥大细胞与慢性马兜铃酸肾病间质纤维化关系的初步探讨[J].中国中西医结合肾病杂志,2005,6(8):441-444. 被引量:4
  • 3陈俊良,吴宜鸿,邓跃毅,陈以平,苏中慧,张恒鸿.丹参对马兜铃酸致肾小管上皮细胞损害的保护作用研究[J].中国中西医结合肾病杂志,2005,6(8):445-448. 被引量:21
  • 4Freundlic M, Jole M, Goodman WG, et al. Bone histology insteroid- treated children with non-azotemic nephrotic syndrome [J]. Pediatr Nephrol, 2004, 19: 400-407.
  • 5Mengs U, Stotzem CD. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology[J]. Arch Toxicol, 1993, 67(5): 307.
  • 6Krumbiegel G, Hallensleben J, Mennicke WH. Studies on themetabolism of aristolochic acids Ⅰ and Ⅱ[J]. Xenobiotica, 1987, 17 (8) : 981.
  • 7Stiborova M, Frei E, Wiessler M, et al. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by cytochromes P450 1A1 and 1A2[J]. Chem Res Toxicol, 2001, 14(8): 1128.
  • 8Stiborova M, Frei E, Sopko B, et al. Carcinogenic aristolochic acids upon activation by DT-diaphorade form adducts found in DNA of patients with Chinese herbs nephropathy[J]. Carcinogenesis, 2002, 23(4): 617.
  • 9Ji L, Zhang L, Jiang Z, et al. Toxicities of aristolochic acid I and aristololactam I in cultured renal epithelial cells[J]. Toxico In Vitro, 2010, 24(4) : 1092-1097.
  • 10Mengs U. Acute toxicity of aristolochic acid in rodents[J]. Arch toxicol, 1987, 59(5): 328.

共引文献67

同被引文献180

引证文献16

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部